

A Comparative Discussion on the Selection of Cardiac Hypertrophy Models: TAC Surgery Vs Ang II Infusion [Letter]

Huiye Yang, Xiaotao Wang

Department of Hematology, The Affiliated Hospital of Guilin Medical University, Guilin, People's Republic of China

Correspondence: Huiye Yang; Xiaotao Wang, Department of Hematology, The Affiliated Hospital of Guilin Medical University, Guilin, People's Republic of China, Email huiyeyang1@163.com; wxw99321@163.com

Dear editor

We reviewed the article by Yang et al titled “Apigenin Attenuates Transverse Aortic Constriction-Induced Myocardial Hypertrophy: The Key Role of miR-185-5p/SREBP2-Mediated Autophagy” published in your esteemed journal.¹ This study offers new insights into the treatment of cardiac hypertrophy, demonstrating that targeting specific miRNAs and autophagy pathways could lead to the development of novel therapeutic strategies. We sincerely appreciate the rigorous efforts and valuable contributions made in this research.

However, we noticed that the study employed two different models for investigating in vivo and in vitro cardiac hypertrophy mechanisms. Specifically, the in vivo experiments utilized Sprague-Dawley (SD) rats to create a Transverse Aortic Constriction (TAC) model, while the in vitro experiments involved Angiotensin II (Ang II)-induced hypertrophy in cardiomyocytes. In contrast, the study by Ye et al used chronic Ang II infusion to establish an in vivo cardiac hypertrophy model.² We have a few thoughts regarding the decision to use different modeling approaches in this study:

First, Ang II injection is relatively simple, requiring no complex surgical procedures, while TAC surgery is more complicated, demanding proficient surgical skills and careful postoperative care to avoid complications. Second, Ang II injection affects multiple systems, potentially causing non-cardiac-related side effects such as vasoconstriction and increased renal burden, making it difficult to focus solely on cardiac structural remodeling.³ In contrast, TAC surgery primarily targets the heart, allowing for more precise study of cardiac functional changes with reduced interference from other systems. Additionally, the dosage and duration of Ang II injection must be carefully controlled to avoid systemic effects that introduce variability. On the other hand, the TAC model achieves precise control of pressure overload through surgery, leading to more reproducible experimental results.⁴ Moreover, the systemic effects of Ang II result in greater pharmacokinetic variability between individuals, which may increase the variability of experimental outcomes. In contrast, the TAC model relies less on endocrine and other systems due to its mechanical nature, improving the reliability of results. Lastly, a meta-analysis on the TAC model indicated that specific mouse strains, gender, and age significantly influence the quality of the model, but these confounding factors can be controlled through experimental design.⁵

In conclusion, although TAC surgery is more complex, we believe that through careful optimization of procedures and experimental design, the TAC model can provide more reliable results compared to direct Ang II injection.

Funding

There is no funding to report.

Disclosure

The authors declare no potential conflict of interest in this communication.

References

1. Yan N, Wang X, Xu Z, Zhong L, Yang J. Apigenin attenuates transverse aortic constriction-induced myocardial hypertrophy: the key role of miR-185-5p/SREBP2-mediated autophagy. *Drug Des Devel Ther*. 2024;18:3841–3851. doi:10.2147/DDDT.S464004
2. Ye S, Huang H, Han X, et al. Dectin-1 Acts as a non-classical receptor of Ang II to induce cardiac remodeling. *Circ Res*. 2023;132(6):707–722.
3. Leite APO, Li XC, Nwia SM, Hassan R, Zhuo JL. Angiotensin II and AT(1a) receptors in the proximal tubules of the kidney: new roles in blood pressure control and hypertension. *Int J Mol Sci*. 2022;23(5):2402. doi:10.3390/ijms23052402
4. Wang X, Zhu X, Shi L, et al. A time-series minimally invasive transverse aortic constriction mouse model for pressure overload-induced cardiac remodeling and heart failure. *Front Cardiovasc Med*. 2023;10:1110032. doi:10.3389/fcvm.2023.1110032
5. Bosch L, de Haan JJ, Bastemeijer M, et al. The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis. *Heart Fail Rev*. 2021;26(6):1515–1524. doi:10.1007/s10741-020-09960-w

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S497043>